Login or create an accountClose
I am a returning customer
Login or create an accountClose
Your Account Has Been Created!
Thank you for registering with MedsDots!
You will be notified by e-mail once your account has been activated by the store owner.
If you have ANY questions about the operation of this online shop, please contact the store owner.
You have been logged off your account. It is now safe to leave the computer.
Your shopping cart has been saved, the items inside it will be restored whenever you log back into your account.
samarth iressa 250mg zd1839 tablets
- Product Code: Unigef 250mg Tablets
Brand Name: Unigef
International Brand Name: Iressa 250mg
Contents: Gefitinib 250 mg
Strength: 250 mg
Manufactured by: Samarth Life Sciences Pvt. Ltd.
Packing: Pack of 30 tablets
what is unigef (indian gefitinib 250mg)?
indian gefitinib 250mg tablets is a targeted therapy that targets and binds to the epidermal growth factor receptors (egfr) on the surface of the cell. egfr is found on the surface of many normal and cancer cells. by binding to these receptors iressa® blocks an important pathway that promotes cell division. unigef is classified as a signal transduction inhibitor (epidermal growth factor receptor (egfr) tyrosine kinase inhibitor). medsdots.net is a diversified global healthcare leader focused on supplying drugs to pharmacies, hospitals, clinics and other healthcare providers to ease the access of medications to people all over the world. medsdots, store and export a wide range of medical products in the major therapeutic areas like oncology, hepatitis, hiv/aids, arthritis and others with worldwide shipping service including countries like usa, uk, uae, hong kong, vietnam, cambodia, philippines, china, russia, venezuela, malaysia, singapore and many others. to get more information call or ping us now at : +91-9953810074, wechat/skype: medsdots, qq: 3232648085, email: firstname.lastname@example.org.
indian iressa (unigef 250mg tablets) uses:-
generic gefitinib 250mg tablets for the treatment of locally advanced or metastatic non-small cell lung cancer, after failure of both platinum-based and taxane-based chemotherapies. unigef 250mg tablets is a targeted therapy that targets and binds to the epidermal growth factor receptors (egfr) on the surface of the cell. egfr is found on the surface of many normal and cancer cells. by binding to these receptors gefitinib blocks an important pathway that promotes cell division.
possible side effects of indian gefitinib 250mg (unigef 250mg tablets):-
-most people do not experience all of the side effects listed.
-side effects are often predictable in terms of their onset and duration.
-side effects are almost always reversible and will go away after treatment is complete.
-there are many options to help minimize or prevent side effects.
-there is no relationship between the presence or severity of side effects and the effectiveness of the medication.
the following side effects are common (occurring in greater than 30%) for patients taking gefitinib:
-skin reaction (rash, acne)
these side effects are less common side effects (occurring in about 10-29%) of patients receiving gefitinib:
-before starting gefitinib treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.). do not take aspirin, or products containing aspirin unless your doctor specifically permits this.
-do not receive any kind of immunization or vaccination without your doctor's approval while taking gefitinib.
-inform your health care professional if you are pregnant or may be pregnant prior to starting this treatment. pregnancy category d (gefitinib may be hazardous to the fetus. women who are pregnant or become pregnant must be advised of the potential hazard to the fetus.)
-for both men and women: do not conceive a child (get pregnant) while taking gefitinib. barrier methods of contraception, such as condoms, are recommended. -discuss with your doctor when you may safely become pregnant or conceive a child after therapy.
-do not breast-feed while taking this medication.